Search
forLearn
5 / 801 resultsResearch
5 / 1000+ resultsresearch The effects of Finasteride on the expression of Dazl, Tsga10, Sycp3, Prm2 genes during spermatogenesis in testes of NMRI mice
Finasteride, at doses of 5mg or higher, may negatively affect male fertility by reducing the expression of certain genes involved in sperm production.
research Effects of androgen on extracellular vesicles from endothelial cells in rat penile corpus cavernosum
Low androgen levels reduce nitric oxide production in rat penile cells.
research Exploring the Role of Uc-Msc-Derived Exosomes in Boosting Hhdpcs Proliferation for Hair Growth Via Akt Activation
UC-MSC-derived exosomes may help treat hair loss by promoting hair cell growth through AKT activation.
research BRCA2 in abscission
The tumor suppressor BRCA2 helps in cell division by bringing key proteins to the area where cells split.
research UTILIZAÇÃO DE FINASTERIDA NO TRATAMENTO DA HIPERPLASIA PROSTÁTICA BENIGNA – RELATO DE CASO
Finasteride effectively treats BPH but requires continuous use to maintain benefits.
Community Join
5 / 1000+ resultscommunity GT20029 - Stand-alone Saviour or just part of the stack?
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community GT20029 phase II results release date?
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.